查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088765

全球藥品生產市場：2026-2032年市場預測（依藥物類型、分子類型、劑型、生產階段、生產技術、治療領域、年齡層及通路分類）

Pharmaceutical Manufacturing Market by Drug Type, Molecule Type, Dosage Form, Manufacturing Stage, Manufacturing Technology, Therapeutic Area, Age Group, Distribution - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，製藥製造市場將成長至 12,434.8 億美元，複合年成長率為 7.90%。

主要市場統計數據
基準年 2025 7298億美元
預計年份：2026年 7854.2億美元
預測年份：2032年 12434.8億美元
複合年成長率 (%) 7.90%

製藥製造執行摘要

製藥生產正從產能主導模式轉向科學主導、數位化控制和合規導向的營運模式。推動這一成長的因素包括生物製藥、無菌注射劑、高活性原料藥（API）、連續生產、個人化醫療以及具有韌性的藥品供應鏈。

製造業的變革性變化

隨著製藥公司對傳統批次生產系統進行現代化改造、加強供應商合格、改善污染控制策略並採用先進的流程分析技術，製藥生產格局正在改變。修訂後的歐盟GMP附件1、ICH Q9(R1)、ICH Q10以及全球序列化要求，提高了人們對確保無菌性、風險管理和端到端產品可視性的期望。

人工智慧（AI）的累積影響

人工智慧（AI）正逐漸成為整體製藥生產過程中不可或缺的基礎技術，尤其是在偏差檢測、預測性維護、視覺檢測、製劑開發、批記錄審核、製程最佳化、需求預測和供應計劃等領域，其應用日益廣泛。人工智慧與檢驗的數據、電子品管系統、生產執行系統和GMP管理系統結合，有助於加快決策速度。

主要區域趨勢：亞太地區、北美地區、歐洲地區、拉丁美洲地區、中東和非洲地區

以中國、印度、日本、韓國、澳洲和東協為首的亞太地區，正透過大規模原料藥生產、生物相似藥投資、疫苗生產以及不斷成長的國內醫療保健需求，鞏固其在製藥領域的地位。公共政策的支持、高素質的科技人才以及日益完善的監管體系，正推動全部區域生產更複雜的原料藥和製劑。

關鍵集團概況：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在醫療保健、監管合作以及對價格合理藥品的需求不斷成長的推動下，東協在藥品包裝、學名藥、契約製造和區域供應多元化方面發揮著日益重要的作用。海灣合作理事會（GCC）正利用其國家產業戰略，推進藥品、疫苗、灌裝和包裝流程以及生物製藥領域的本土化能力建設，同時提升採購韌性和醫療安全水平。

主要製藥生產市場的關鍵國別洞察

美國在FDA監管的創新、生物製藥、細胞和基因療法、無菌注射劑、連續生產以及強大的CDMO（合約研發生產組織）網路方面處於主導地位。同時，加拿大支持先進療法、疫苗、從臨床到商業化生產的過渡以及以品質為中心的藥品生產。墨西哥和巴西在美洲的學名藥、包裝、以可及性為導向的生產和供應支援方面發揮著至關重要的作用。

業界領導者使用的實用建議

產業領導者應優先考慮檢驗的數位轉型、品質源於設計 (QbD) 的實施、污染控制、供應商風險評估以及關鍵原料藥、添加劑、一次性組件和包裝材料的雙重採購。投資決策應優先考慮能夠處理生物製藥、無菌產品、高活性化合物、疫苗和複雜學名藥的靈活、模組化和節能型設施。

調查方法

本執行摘要基於系統的二手資料研究，研究資料包括監管指南、檢查和合規參考材料、公開文件、政府衛生數據、行業資訊來源、科學文獻、藥典以及廣受認可的行業出版物。資訊來源包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO)、國際人用藥品註冊技術協調會 (ICH)、經濟合作暨發展組織 (OECD)、世界銀行、聯合國貿易資料集、各國衛生機構、上市公司資訊披露。

結論

製藥生產正步入一個互聯互通程度日益提高、監管日益嚴格、先進技術應用日益廣泛的新階段。能夠兼顧嚴謹的科學研究和強大的營運能力的企業，將更有能力應對藥品短缺、合規壓力、成本控制、永續性預期以及對複雜療法的需求等挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 藥品製造市場：依藥品類型分類

  • 生物相似藥
  • 品牌藥品
  • 學名藥

第8章：製藥製造市場：依分子類型分類

  • 高分子量藥物
  • 小分子藥物

第9章：藥品生產市場：依劑型分類

  • 液體
    • 解決方案
    • 懸浮液
  • 注射劑型
    • 靜脈注射
    • 注射藥物
  • 固態劑型
    • 膠囊
    • 粉末
    • 藥片
  • 外用
    • 軟膏
    • 奶油
    • 凝膠
    • 洗劑
  • 吸入
  • 經皮吸收貼劑
  • 眼藥水

第10章：藥品製造市場：依製造階段分類

  • 原料藥（API）生產
  • 製藥生產
  • 貼上包裝標籤

第11章 製藥製造市場：依製造技術分類

  • 大量生產
  • 連續製造
  • 免洗技術

第12章 藥品製造市場：依治療領域分類

  • 心血管系統
  • 胃腸病學
  • 免疫學
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 呼吸系統

第13章 藥品製造市場：依年齡層別分類

  • 兒童和青少年
  • 成人
  • 老年人

第14章 藥品製造市場：依通路分類

  • 直銷
  • 批發商/經銷商
  • 零售藥房
  • 線上/電子商務藥房
  • 醫院藥局配送

第15章 醫藥製造市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 藥品製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 藥品製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Croda International Plc
  • CSL Limited
  • Divi's Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, inc.
  • Lupin Ltd.
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.
Product Code: MRR-22146147675F

The Pharmaceutical Manufacturing Market is projected to grow by USD 1,243.48 billion at a CAGR of 7.90% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 729.80 billion
Estimated Year [2026] USD 785.42 billion
Forecast Year [2032] USD 1,243.48 billion
CAGR (%) 7.90%

Pharmaceutical Manufacturing Executive Summary

Pharmaceutical manufacturing is moving from capacity-led production to science-led, digitally controlled, and compliance-centered operations. Growth is being shaped by biologics, sterile injectables, high-potency APIs, continuous manufacturing, personalized therapies, and resilient pharmaceutical supply chains.

Verified signals from FDA, EMA, WHO, ICH, and public regulatory disclosures show that GMP compliance, quality assurance, traceability, data integrity, and speed-to-market now define competitive advantage across drug substance and drug product manufacturing.

Transformative Shifts in the Manufacturing Landscape

The pharmaceutical manufacturing landscape is shifting as manufacturers modernize legacy batch systems, strengthen supplier qualification, improve contamination control strategies, and adopt advanced process analytical technology. Revised EU GMP Annex 1, ICH Q9(R1), ICH Q10, and global serialization requirements have increased expectations for sterility assurance, risk management, and end-to-end product visibility.

At the same time, demand for biologics, oncology therapies, vaccines, orphan drugs, and specialty medicines is expanding the need for flexible facilities, aseptic fill-finish capacity, cold chain readiness, and CDMO partnerships supported by validated automation, electronic batch records, and compliant digital quality systems.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer across pharmaceutical manufacturing, especially in deviation detection, predictive maintenance, visual inspection, formulation development, batch record review, process optimization, demand sensing, and supply planning. AI supports faster decisions when integrated with validated data, electronic quality management systems, manufacturing execution systems, and GMP controls.

The cumulative impact is improved right-first-time performance, fewer unplanned shutdowns, stronger process understanding, and earlier detection of quality signals. However, regulated AI adoption requires explainability, audit trails, cybersecurity controls, model governance, human oversight, and alignment with FDA, EMA, ICH, data integrity principles, and GAMP 5 expectations.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is strengthening its pharmaceutical manufacturing position through large-scale API production, biosimilar investment, vaccine manufacturing, and expanding domestic healthcare demand, led by China, India, Japan, South Korea, Australia, and ASEAN economies. Public policy support, skilled scientific labor, and rising regulatory maturity are encouraging more complex drug substance and drug product production across the region.

North America remains a high-value hub for innovation, biologics, sterile injectables, advanced therapies, continuous manufacturing, and FDA-regulated quality systems, while Europe benefits from strong EMA oversight, mature GMP infrastructure, serialization compliance, and specialty drug production. Latin America is improving local manufacturing for essential medicines, vaccines, generics, and packaging to strengthen medicine access and reduce import dependency. The Middle East is investing in healthcare localization, procurement security, and industrial diversification, while Africa is prioritizing access, technology transfer, regional production resilience, and vaccine manufacturing capacity under public health and development initiatives.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is becoming more relevant for pharmaceutical packaging, generics, contract manufacturing, and regional supply diversification, supported by healthcare expansion, regulatory cooperation, and demand for affordable medicines. The GCC is using national industrial strategies to localize medicines, vaccines, fill-finish operations, and biologics-adjacent capabilities while improving procurement resilience and healthcare security.

The European Union remains a regulatory benchmark for GMP, pharmacovigilance, clinical quality standards, and serialization, influencing global compliance expectations. BRICS markets offer scale, API depth, generics production, expanding biologics demand, and policy support for domestic manufacturing. G7 and NATO countries increasingly emphasize supply security, reshoring of critical medicines, advanced manufacturing technologies, cybersecurity, and protection of essential pharmaceutical supply chains.

Key Country Insights Across Major Pharmaceutical Manufacturing Markets

The United States leads in FDA-regulated innovation, biologics, cell and gene therapy, sterile injectables, continuous manufacturing, and CDMO depth, while Canada supports advanced therapies, vaccines, clinical-to-commercial manufacturing, and quality-driven pharmaceutical production. Mexico and Brazil are important for regional generics, packaging, access-driven production, and supply support across the Americas.

The United Kingdom, Germany, France, Italy, and Spain anchor Europe's high-quality pharmaceutical manufacturing base through advanced GMP capabilities, specialty medicine production, biologics investment, and established export networks, while Russia emphasizes domestic supply resilience and localization of essential medicines. China and India dominate scale-sensitive API, intermediates, and generics capacity, supported by large supplier ecosystems and expanding regulatory capabilities. Japan and South Korea lead in quality-intensive production, biologics, vaccines, and advanced manufacturing, while Australia supports specialty, clinical, biotechnology, and regional manufacturing networks aligned with strict quality standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated digital transformation, quality-by-design implementation, contamination control, supplier risk mapping, and dual-sourcing for critical APIs, excipients, single-use components, and packaging materials. Investment decisions should favor flexible, modular, and energy-efficient facilities that can support biologics, sterile products, high-potency compounds, vaccines, and complex generics.

Executives should build AI governance frameworks, strengthen data integrity programs, improve cyber resilience, and align manufacturing strategy with evolving FDA, EMA, WHO, PIC/S, and ICH expectations. Leaders should also improve scenario planning for medicine shortages, qualify strategic suppliers, enhance workforce training, and integrate sustainability metrics into facility design and process optimization.

Research Methodology

This executive summary is based on structured secondary research using regulatory guidance, inspection and compliance references, public filings, government health data, trade sources, scientific literature, pharmacopeial references, and recognized industry publications. Sources include FDA, EMA, WHO, ICH, OECD, World Bank, UN trade datasets, national health agencies, and public company disclosures.

Insights were validated through triangulation across regulatory, operational, and commercial indicators, with emphasis on manufacturing capacity signals, GMP expectations, supply chain risk, regional production policy, technology adoption trends, quality system maturity, and public health priorities. The analysis avoids market sizing, market share, and forecasting to focus on verified structural and operational developments.

Conclusion

Pharmaceutical manufacturing is entering a more connected, regulated, and technology-enabled phase. Companies that combine scientific rigor with resilient operations will be best positioned to address medicine shortages, compliance pressure, cost control, sustainability expectations, and demand for complex therapies.

Sustainable advantage will depend on trusted quality systems, AI-ready data, regional supply strategies, validated automation, supplier resilience, and disciplined compliance execution across global pharmaceutical manufacturing networks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Manufacturing Market, by Drug Type

  • 7.1. Biosimilars
  • 7.2. Branded Drugs
  • 7.3. Generic Drugs

8. Pharmaceutical Manufacturing Market, by Molecule Type

  • 8.1. Large Molecule Drugs
  • 8.2. Small Molecule Drugs

9. Pharmaceutical Manufacturing Market, by Dosage Form

  • 9.1. Liquid Dosage Forms
    • 9.1.1. Solution
    • 9.1.2. Suspension
  • 9.2. Parenteral Dosage Forms
    • 9.2.1. Infusion Forms
    • 9.2.2. Injectable Forms
  • 9.3. Solid Dosage Forms
    • 9.3.1. Capsule
    • 9.3.2. Powder
    • 9.3.3. Tablet
  • 9.4. Topical
    • 9.4.1. Ointments
    • 9.4.2. Creams
    • 9.4.3. Gels
    • 9.4.4. Lotions
  • 9.5. Inhalation
  • 9.6. Transdermal Patches
  • 9.7. Ophthalmic Solutions

10. Pharmaceutical Manufacturing Market, by Manufacturing Stage

  • 10.1. API Manufacturing
  • 10.2. Formulation Manufacturing
  • 10.3. Packaging & Labelling

11. Pharmaceutical Manufacturing Market, by Manufacturing Technology

  • 11.1. Batch Manufacturing
  • 11.2. Continuous Manufacturing
  • 11.3. Single-Use Technology

12. Pharmaceutical Manufacturing Market, by Therapeutic Area

  • 12.1. Cardiovascular
  • 12.2. Gastroenterology
  • 12.3. Immunology
  • 12.4. Infectious Diseases
  • 12.5. Neurology
  • 12.6. Oncology
  • 12.7. Respiratory

13. Pharmaceutical Manufacturing Market, by Age Group

  • 13.1. Children & Adolescents
  • 13.2. Adults
  • 13.3. Geriatric

14. Pharmaceutical Manufacturing Market, by Distribution

  • 14.1. Direct Sales
  • 14.2. Wholesale / Distributors
  • 14.3. Retail Pharmacy
  • 14.4. Online / E-Commerce Pharmacies
  • 14.5. Hospital Pharmacy Distribution

15. Pharmaceutical Manufacturing Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Pharmaceutical Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Pharmaceutical Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. AbbVie Inc.
  • 19.3. Alkem Laboratories Ltd.
  • 19.4. Amgen Inc.
  • 19.5. Astellas Pharma Inc.
  • 19.6. AstraZeneca plc
  • 19.7. Aurobindo Pharma Ltd.
  • 19.8. Baxter International Inc.
  • 19.9. Bayer AG
  • 19.10. Biogen Inc.
  • 19.11. Boehringer Ingelheim GmbH
  • 19.12. Bristol-Myers Squibb Company
  • 19.13. Cipla Ltd.
  • 19.14. Croda International Plc
  • 19.15. CSL Limited
  • 19.16. Divi's Laboratories Ltd.
  • 19.17. Dr. Reddy's Laboratories Ltd.
  • 19.18. Eli Lilly and Company
  • 19.19. F. Hoffmann-La Roche Ltd.
  • 19.20. Gilead Sciences, Inc.
  • 19.21. GlaxoSmithKline plc
  • 19.22. Johnson & Johnson Services, inc.
  • 19.23. Lupin Ltd.
  • 19.24. Mankind Pharma Ltd.
  • 19.25. Merck KGaA
  • 19.26. Novartis AG
  • 19.27. Novo Nordisk A/S
  • 19.28. Pfizer Inc.
  • 19.29. Sanofi S.A.
  • 19.30. Sun Pharmaceutical Industries Limited
  • 19.31. Takeda Pharmaceutical Company Ltd.
  • 19.32. Teva Pharmaceutical Industries Ltd.
  • 19.33. Thermo Fisher Scientific Inc.
  • 19.34. Torrent Pharmaceuticals Ltd.
  • 19.35. Viatris Inc.
  • 19.36. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LARGE MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LARGE MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LARGE MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUSPENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUSPENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUSPENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARENTERAL DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARENTERAL DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARENTERAL DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFUSION FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFUSION FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFUSION FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CREAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LOTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LOTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LOTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPHTHALMIC SOLUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OPHTHALMIC SOLUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPHTHALMIC SOLUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL API MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL API MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL API MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FORMULATION MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FORMULATION MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FORMULATION MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PACKAGING & LABELLING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PACKAGING & LABELLING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PACKAGING & LABELLING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SINGLE-USE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SINGLE-USE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SINGLE-USE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHILDREN & ADOLESCENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CHILDREN & ADOLESCENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHILDREN & ADOLESCENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIRECT SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIRECT SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIRECT SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL WHOLESALE / DISTRIBUTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL WHOLESALE / DISTRIBUTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL WHOLESALE / DISTRIBUTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ONLINE / E-COMMERCE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONLINE / E-COMMERCE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONLINE / E-COMMERCE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL PHARMACY DISTRIBUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITAL PHARMACY DISTRIBUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITAL PHARMACY DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 279. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 282. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 285. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 287. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 291. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 292. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 294. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 295. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 298. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL PHARMACEUTICAL MANUFACTU